BioCentury
ARTICLE | Financial News

With clear FDA path, Clementia raises $70.2M

October 30, 2018 2:43 PM UTC

Days after revealing regulatory plans for its therapy for a rare bone disease, Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) raised $70.2 million in a bumped-up follow-on offering.

Clementia priced 5.3 million shares at $13.25 late Monday, hours after it proposed to raise $50 million. The price is a 4% discount to the stock’s closing price of $13.80 on Monday, when the company proposed the offering after market hours. Clementia shares dipped $0.63 to $13.17 Tuesday. Underwriters are Morgan Stanley, Leerink and Wedbush PacGrow...

BCIQ Company Profiles

Clementia Pharmaceuticals Inc.